Meglumine antimoniate

From WikiProjectMed
Jump to navigation Jump to search
Meglumine antimoniate
Meglumine antimoniate major component 3D.png
Names
Other namesMeglumine antimonate
  • Hydroxy-dioxostiborane; (2R,3R,4R,5S)-6-methylaminohexane-1,2,3,4,5-pentol
Clinical data
Defined daily dosenot established[1]
External links
AHFS/Drugs.comMicromedex Detailed Consumer Information
Chemical and physical data
FormulaVariable
Molar massVariable
3D model (JSmol)
  • O=[Sb](=O)O.O[C@@H]([C@@H](O)[C@H](O)[C@@H](O)CNC)CO
  • InChI=1S/C7H17NO5.H2O.2O.Sb/c1-8-2-4(10)6(12)7(13)5(11)3-9;;;;/h4-13H,2-3H2,1H3;1H2;;;/q;;;;+1/p-1/t4-,5+,6+,7+;;;;/m0..../s1 checkY
  • Key:XOGYVDXPYVPAAQ-SESJOKTNSA-M checkY

Meglumine antimoniate is a medicine used to treat leishmaniasis.[2] This includes visceral, mucocutaneous, and cutaneous leishmaniasis.[2] It is given by injection into a muscle or into the area infected.[2]

Side effects include loss of appetite, nausea, abdominal pain, cough, feeling tired, muscle pain, irregular heartbeat, and kidney problems.[2] It should not be used in people with significant heart, liver, or kidney problems.[2] It is not recommended during breastfeeding.[2] It belongs to a group of medications known as the pentavalent antimonials.[2]

Meglumine antimoniate came into medical use in 1946.[3] It is on the World Health Organization's List of Essential Medicines.[4] The wholesale cost in the developing world is about 4.32 USD per vial as of 2014.[5] It is available in Southern Europe and Latin America but not the United States.[6][7]

Medical uses

Dosage

The defined daily dose is not established.[1]

Society and culture

It is manufactured by Aventis[8] and sold as Glucantime in France, and Glucantim in Italy.

See also

References

  1. ↑ 1.0 1.1 "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 1 July 2021. Retrieved 21 September 2020.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 183. hdl:10665/44053. ISBN 9789241547659.
  3. ↑ Sneader, Walter (2005). Drug Discovery: A History. John Wiley & Sons. p. 59. ISBN 9780470015520. Archived from the original on 2016-12-20.
  4. ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  5. ↑ "Meglumine Antimonate". International Drug Price Indicator Guide. Archived from the original on 22 January 2018. Retrieved 8 December 2016.
  6. ↑ Bope, Edward T.; Kellerman, Rick D.; Rakel, Robert E. (2010). Conn's Current Therapy 2011: Expert Consult. Elsevier Health Sciences. p. 95. ISBN 143773572X. Archived from the original on 2016-12-20.
  7. ↑ Gorbach, Sherwood L.; Bartlett, John G.; Blacklow, Neil R. (2004). Infectious Diseases. Lippincott Williams & Wilkins. p. 355. ISBN 9780781733717. Archived from the original on 2016-12-20.
  8. ↑ Aventis press release Archived 2014-05-22 at the Wayback Machine, 15 April 2005. (in German)

External links

Identifiers:
Retrieved from "https://mdwiki.org/w/index.php?title=Meglumine_antimoniate&oldid=1332417"